compani
rais ep lower tax
nme/nilex pipelin street upsid
maintain sale vs street rais ep
street top-end lli rang model
sales/ep cagr vs street
expect see faster bottom-lin growth op margin expand
vs street think ideal posit drive
sig support dividend growth share repo esp oncology/
immunolog reiter ep support dcf
rais ep street divers growth
maintain total revenu top-end lli
rang vs street rais ep
street top-end lli rang
lower tax rate lower share count model robust sale growth
compound-annual-growth-rate vs street driven
volum across major geographi us europ japan row
growth driven three market asset trulic jardianc basaglar
 three pipelin asset intranas glucagon ultra-rapid insulin lispro
nilex opportun underappreci view mirankizumab
pso data encourag oncolog verzenio drive solid growth
addit busi develop bd need re-load
late-stag pipelin ahead alimta us loss-of-exclus loe look
neuro/pain pipelin asset emgal launch lasmiditan file
tanezumab lt safeti data add anoth materi leg growth
model assum grow ep faster sale
ep compound-annual-growth-rate base expand oper margin vs street
 declin share count model
strong balanc sheet leverag consider financi
flexibl return cash sharehold via rise dividend
share repo ytd pursu esp oncolog immunolog
reiter ep risk includ price pressur
esp diabet commerci execut regulatory/clin trial risk
tr target
compani
diabet growth benefit precedent-set rewind
lli diabet busi lli largest segment sale also fastest
most-diversifi growth driver model diabet total revenu includ
collabor revenu compound-annual-growth-rate driven robust growth
trulic jardianc basaglar risk-adjust sale three pipelin asset
offset expect declin sale legaci insulin humalog/humulin due competit
lli trulic volum share us market grow yoy
project us market approach vs street announc posit
top-lin data rewind cv outcom trial see note view rewind
result precedent-set full data present ada june san francisco
reward less sick patient follow longer period time vs novo nordisk nvo
rate trial ozemp see trial design comparison expect trulic remain
class leader least model trulic global sale vs street
 partner boehring ingelheim bi privat market inhibitor jardianc
us trx share market grow yoy market per model
near-term expect jardianc continu take share johnson johnson rate
invokana due inferior label see note safeti concern long-term expect lly/bi
drive global growth label expans two on-going trial jardianc heart
failur emperor-reduc emperor-preserv could stop earli interim analysi
 two emperial-reduc emperial-preserv primari complet may
model jardianc allianc revenu vs street growth also driven
lli biosimilar insulin glargin basaglar model vs street
lesser extent lly/bi tradjenta vs street expect gain share
declin class base posit cv outcom benefit carmelina pipelin front
three asset could contribut meaning sale beyond near-term
intranas glucagon review us/eu hypoglycemia model launch risk-
adjust sale vs street addit ultra-rapid insulin lispro
trial model launch risk-adjust sale vs street
also roll trial tirzepatid co-agonist late show
best-in-class efficaci trial see note model launch risk-adjust sale
vs street also note enter agreement chugai subsidiari
roch rog-ch rate in-licens oral non-peptid agonist expect
initi trial near-term
oncolog need extern asset grow post-alimta loe
lli oncolog busi intrigu intern asset solid growth potenti
model sale view howev alimta expect
lose exclus us think need sourc meaning extern innov
hope grow oncolog global sale loe period lli verzenio abemaciclib
shown earli success despit third breast cancer market
track ahead novarti nv rate kisqali model verzenio sale vs street
see meaning upsid our/street estim verzenio show posit data adjuv
breast cancer monarch studi primari complet april tumor type
growth asset lli portfolio includ cyramza in-lin street
current use gastric cancer review us pdufa alimta
vs street see modest growth us loe base
uptak merck buy keytruda alimta nsq nsclc lartruvo
vs see solid uptak soft tissu sarcoma us eu emerg market
deep pipelin oncolog asset least clinic trial early-stag
one late-stag asset pegilodecakin pegyl sequoia
pancreat cancer primari complet march model late launch
risk-adjust pegilodecakin sale vs street recent meet manag
see note acknowledg focus in-licens collabor secur
next wave innov complet three bd deal ytd includ two acquisit aurka
page
compani
click note armo click collabor agreement
privat
immunolog street mostli nilex
lli immunolog franchis fairli new taltz launch us expect immunolog
sale grow primarili underappreci new indication/label
expans nilex opportun taltz olumi lli inhibitor taltz benefit
bifurc psoriasi pso market taltz two in-class
competitor nv cosentyx valeant vrx rate siliq well us/eu launch
psoriat arthriti plan file taltz us axial spondyloarthr axspa base
coast-v coast-w trial see note expect approv help drive
growth model taltz sale street competit front ucb ucb-
rate uniqu bimekizumab neutral vs taltz cosentyx
neutral siliq inhibitor five on-going trial pso
expect read-out trial begin
lli jak inhibitor olumi uninspir launch us rheumatoid arthriti sinc
approv june total us sale slow ramp surpris
view given olumi label disadvantag vs hold xeljanz/xr exclus
dose fortun olumi see much stronger uptak ex-u dose
approv particularli europ addit robust nilex clinic plan olumi
on-going psoriat arthriti initi alopecia areata on-going base
estim around trial time think olumi could approv assum posit data
four nilex opportun add materi long-term growth model
olumi sale vs street addit taltz/olumi nilex opportun
sever nme pipelin notabl inhibitor mirikizumab
pso ulcer coliti uc crohn diseas cd remind see note
present impress data mirikizumab pso aad march includ pasi
score dose vs placebo model mirikizumab
launch risk-adjust sale vs street
neuro/pain grow compound-annual-growth-rate entir driven pipelin
lli in-lin neurosci product zyprexa cymbalta strattera prozac peri-lo
major market declin doubl digit annual growth lli neuroscience/
pain franchis model driven emgal approv sept lasmiditan file
 tanezumab expect neuroscience/pain franchis repres fourth leg growth
diabet immunolog oncolog compound-annual-growth-rate launch emgal
competit label migrain prophylaxi market high unmet medic need
think emgal differenti label vs cgrp label includ
efficaci data result function measur emgal earlier onset effect induct
dose conveni inject devic comprehens label give sale forc advantag
field vs nv rate aimovig teva teva rate ajovi
view importantli also receiv breakthrough therapi design emgal cluster
headach plan file snda cluster headach note previous see
note titl cgrp show efficaci benefit debilit cluster headach
emgal show signific reduct number weekli cluster headach attack primari endpoint
vs placebo studi c-gal note call emgal efficaci cluster
headach set provid halo effect across emgal migrain in-lin think see
note final view lli aggress commerci approach potenti enabl emgal
secur share posit class despit third-to-market on-going aggress
sampl discount competit cgrp manufactur remind amgn/nv make
aimovig avail co-pay maximum benefit cap unlik ajovi
co-pay outsid us expect emgal approv europ posit chmp
opinion sept japan model lli emgal global sale
street
lasmiditan expect file nda treatment acut migrain
expect fda action note deep-div see note titl colucid deal add
page
compani
innov acut migrain asset pain segment quiver view lasmiditan novel compound
differenti moa posit take share annual triptan trx acut
migrain set la sale street investor attent also
focus upcom read-out tanezumab pfe/lli anti-nerv growth factor ngf monoclon
antibodi remind tanezumab met three co-primari endpoint phase oa trial
 full result present acr show toler safeti profil case osteonecrosi
rapidli progress osteoarthr ropa seen tanezumab treat patient vs placebo
arm pfe/lli expect three remain trial tanezumab oa oa efficaci
long-term safeti chronic low back pain tango read
earli tanezumab add high-margin allianc revenu lli emerg pain franchis model
heavili risk adjust sale vs street
within neurosci consid lli alzheim clinic develop effort high-risk/high-
reward opportun despit multipl high-profil setback continu invest alzheim
franchis share discontinu bace inhibitor treatment arm
phase studi trailblazer-alz treatment earli symptomat alzheim diseas base
limit efficaci increas rate brain shrinkag psychiatr advers event howev lli
monotherapi treatment arm continu studi lli tau deposit monoclon antibodi
also phase earli symptomat ad patient primari complet januari
also pursu oral compound act dopamin receptor
enhanc treatment parkinson diseas dementia current enrol patient
trial presenc primari complet juli final posit
phase result flortaucipir sept plan discuss result regul
near-term lli alzheim pipelin becom de-risk clinic could see materi upward
pressur our/street long-term sales/ep estim lli neuro/pain franchis
catalyst-rich new product cycl unfold
lly/bi jardianc heart failur pivot trial emperor-reduc -preserv like stop
earli interim analys opinion plan initi program tirzepatid
co-agonist late earli aim file taltz treat axial spondyloarthr
axspa regul expect ema jpmda action emgal episodic/chron
migrain olumi sle trial alopecia areata underway plan
initi lli dec investor event focus financi rang pipelin
progress product gain pfe/lli expect read-out three remain trial
tanezumab earli announc posit top-lin data trulic rewind
expect full data ada june exhibit catalyst calendar year-end
page
compani
one-off guidanc updat sigilon deal
page
compani
sale
net incom sharehold
sale
net incom sharehold
page
compani
exhibit estim strh vs consensu
page
compani
page
compani
page
compani
expect ema approv emgal prevent episodic/chron migrain
readout cv outcom trial oral semaglutid
expect read-out azn farxiga studi
start trial jardianc chronic kidney diseas ckd
expect jpmda approv emgal prevent episodic/chron migrain
submit snda taltz axial spondyloarthr
submit snda emgal cluster headach
expect fda label updat alimta includ data nsq nsclc
start trial olumi psoriat arthriti
start trial tirzepatid type diabet
estim launch lasmiditan oral us market
expect fda approv base os data
readout second cv outcom studi carolina
submit empagliflozin linagliptin metformin xr type diabet
phase trial durat osteoarthr oa hip knee
phase long-term safeti trial osteoarthr oa hip knee
data relay studi cyramza roch tarceva egfr nsclc
phase tango trial chronic lower back pain
pdufa zynquista sotagliflozin dual inhibitor treatment type diabet
primari complet heart failur trial emperial-reduced/preserv trial walk test
pre-clin trial identifi biomark predict dev alzheim diseas
expect fda/ema approv intranas glucagon hypoglycemia
expect ema/jpmda approv base os data
primari complet studi galunisertib xtandi mcrpc
primari complet head-to-head studi taltz vs tremfya moderate-to-sever plaqu psoriasi
announc trial sarcoma
expect fda approv inclus carmelina cv outcom data tradjenta label
expect fda approv lasmiditan acut migrain
expect fda approv taltz axial spondyloarthr
expect fda approv emgal cluster headach
submit nda tanezumab
poc arrow trial nv cosentyx vs tremfya pso resist treatment stelara
page
compani
exhibit incom statement
sale
net incom sharehold
page
compani
exhibit consolid balanc sheet
total liabil sharehold equiti
equival
st borrow current portion lt debt
accumul comprehens loss
common stock treasuri
page
compani
exhibit statement
chang defer tax
net oper
restrict cash releas acquisit
dispos prop equip
addit asset
reduct invest
addit invest
net invest
purchas common stock
chang st borrow cpltd
addit long-term debt
reduct long-term debt
net financ
effect exchang rate
cash/equival begin period
cash/equival end period
page
compani
lilli lead research-bas biopharmaceut compani focus drug discoveri
clinic develop manufactur commerci pharmaceut product human
anim diseas gener sale yoy gener
us ex-u market human medicin busi includ core franchis
neurosci diabet women oncolog cardiovascular contribut
 total sale global leader diabet arena new product
trulic basaglar collabor asset jardianc tradjenta lli oncolog franchis
compris inhibitor verzenio abemaciclib alimta cyramza portrazza lartruvo
also place stake ground establish immunolog franchis
launch taltz olumi lli fourth leg emerg growth target pain market
enter commerci phase emgal derisk late-stag asset lasmiditan
tanezumab enter one best new product cycl year histori new product
rate buy base attract low-teen earn growth mid-singl
digit volum driven sale growth commit expand oper margin tight
cost manag new product cycl unfold
model assum doubl diabet franchis level
jardianc basaglar trulic offset declin establish product
humalog humulin expect jardianc take materi share market older
gener therapi owe cardiovascular-benefit estim share shift
older gener therapi jardianc equat sale conting discount rebat
put upward pressur out-year estim also expect grow oncolog
franchis support verzenio alimta cyramza portrazza lartruvo verzenio third-to-market
inhibitor segment multipl use breast cancer market alimta expect
benefit combo use keytruda first-lin non-smal cell lung cancer nsclc
immunolog taltz olumi baricitinib expect contribut sale
think olumi long-term growth benefit expand asset commerci reach much
possibl geograph eu/japan label expans atop dermat system lupu
erythematosu psoriat arthriti taltz posit captur mid-teen percentag psoriasi
treat patient popul next five year lastli lli emerg pain franchis repres
fourth leg growth differenti late-stag asset significantli derisk lasmiditan
tanezumab recent launch emgal emgal robust efficaci placebo-lik safeti posit
take materi share cgrp market lasmiditan first-in-class molecul
offer cardiovascular safeti advantag acut migrain standard-of-car triptan
oper leverag margin expans central thesi compani contain fix cost
grow revenu base next five year streamlin oper improv
cost structur posit achiev opex goal sale
valuat risk
pt assum trade ep reflect premium current
forward group averag forward price-to-earnings multipl think premium group averag
multipl justifi given lli diversifi volume-driven sale growth mid-singl digit sale
compound-annual-growth-rate oper leverag oper margin goe price
target support discount cash flow dcf intrins valu per share
risk thesi revolv around price commerci execut regulatori clinic risk
face upcom patent expir ciali alimta well recent
expir patent strattera competit pressur trulic semaglutid humalog
page
compani
biosimilar insulin lispro expect off-set four launch verzenio emgal
olumi lasmiditan
compani mention note
amgen inc rate
bausch health compani inc vrx rate
johnson johnson rate
novarti ag nv rate
novo nordisk a/ nvo rate
roch hold ltd genusssch rog-ch rate
teva pharmaceut industri limit teva rate
ucb ucb-b rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
